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ABSTRACT 
The administration of medicine has improved enormously over the years, but the 
completion of the human genome sequence at the start of the 21st century is now rapidly ushering 
in a new era within medicine. With genome kits available online and holiday sales on human 
genome sequencing the ability to sequencing one’s genome is rapidly changing the face of 
medicine and has led to the promise of ‘personalized medicine’. This IQP attempts to look at the 
impact that the revolutionary field of genomics is having on the administration of medicine.   
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PROJECT OBJECTIVES 
 
The objective of this IQP project was to begin to examine the impact of genomics on medicine.  
In today’s society medical care is delivered almost exclusively by physicians and other health 
care professionals.  The advent of genomics has led to companies providing direct to consumer 
(DTC) services involving medical information relevant to health care.  The outcome of this 
project suggests that we are entering an era of “personalized” and “global” medicine, but also 
one that could remove an important component - physicians and other health care professionals, 
from the process. 
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CHAPTER 1: DNA – Discovery and Era of Recombinant DNA/Molecular 
Biology 
 
DNA – STRUCTURE   
The cell is known as the basic unit of life and the genetic instruction of cells in all living 
organisms and some viruses is Deoxyribonucleic acid, commonly known as DNA.  This 
discovery and the unraveling of the structure of DNA were critical first steps in the development 
of the field of genomics (National Human Genome Research Institute, 2010).   
At the molecular level, DNA gets its name from the sugar that it contains - deoxyribose.  
This five-carbon sugar (pentose) forms an essential component of the building blocks of DNA 
termed nucleotides.  Nucleotides are made up of the sugar molecule (deoxyribose), a phosphate 
group, and nitrogenous bases (purines and pyrimidines).  A nitrogenous base plus deoxyribose 
forms a nucleoside and the addition of the phosphate group generates the nucleotide.  There exist 
four nucleotides: thymine, cytosine, adenine, and guanine.  The nucleotides adenine and guanine 
are known as purines because they have a six-membered and a five-membered nitrogen-
containing ring fused together.  The nucleotides thymine and cytosine on the other hand are 
known as pyrimidines because they have only a six-membered nitrogen-containing ring fused 
together.  A single strand of DNA is formed when these nucleotides are linked together through 
phosphodiester bonds formed between the 3’ hydroxyl group on the sugar and 5’ phosphate 
group.   
Solution of the structure of DNA revealed that it has a very unique double helical 
structure with two antiparallel strands pairing through the nucleotides (National Human Genome 
Research Institute, 2010).  Nucleotides of the DNA molecule are complementary--meaning the 
sequence of nucleotides on one DNA strand determines the sequence of nucleotides on the other 
strand.  This is because under normal conditions nucleotides pair (via hydrogen bonds) with only 
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one other type of nucleotide.  This specificity of nucleotide bonding between the two strands of 
DNA helps creates the well-known double helical structure of DNA as shown in Figure 1 below.  
The nucleotide pairing is in 
such a way that a purine is 
always bonded to a 
pyrimidine.  In a normal 
DNA double helix, adenine 
pairs with thymine through two 
hydrogen bonds and guanine 
pairs with cytosine through three hydrogen bonds.  Each nucleotide pair in the double helix is 
then commonly referred to as a base pair (for larger 
sequences of base pairs, one thousand base pairs equal one 
kilobase of DNA, while a million base pairs equal a 
megabase of DNA).  Hydrogen bonds are relatively weak 
bonds, thus providing a key element of the ability of the two 
strands of DNA to be separated or unzipped.  These 
unzipped strands can then be used as templates for the 
synthesis of additional copies of that DNA molecule; a 
process that underlies the field of DNA sequencing 
and genomics (Figure 2). 
 
 
 
Figure 1: DNA Structure. (Taken from: Google Images: metal-
domes.com) 
 
Figure 2: DNA Replication. Unzipping DNA 
provides two templates for the formation another 
Double Helix. (Taken from: Google Images: 
biocorner.com) 
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DNA - GENES AS FUNCTIONAL UNITS  
To understand the role of DNA in controlling traits it is important to understand the 
central dogma of molecular biology, which states that information flows directionally from DNA 
to RNA to protein (Gerstein et…al, 2007; 
Figure 3).  In its simplest form this 
information, a functional unit of DNA, is 
called a gene and can vary from hundreds 
to thousands of base pairs long.  Through 
the process of transcription, genes are 
then transcribed (copied) into 
Ribonucleic acid (RNA), which is then read into a sequence of amino acids to form proteins 
through the process of translation.  More recently however, the importance of RNA molecules 
and not proteins as the functional end for the flow of information from genes has become 
increasingly evident (Gerstein et…al, 2007).   
At the molecular level, genes have two basic components, the transcription unit, or 
portion of DNA sequence that is physically copied into RNA, and the regulatory region that 
directs when and in what cells the gene will be transcribed (Gerstein et…al., 2007; Dillon 
et…al,. 2000).  For genes encoding proteins, within the transcription unit lies the open reading 
frame or DNA sequence that is read in triplets (codons) to specify the correct sequence of amino 
acids in the protein (Dillon et…al,. 2000). At a higher level, genes are organized onto 
chromosomes, which allow for the proper segregation of genes from generation to generation.  
Through the proper segregation of chromosomes through a process called meiosis, genes can be 
passed on from parents to offspring.   
 
Figure 3: Central Dogma of Biology. DNA is transcribed 
into RNA which is then translated into protein.  
(Taken from: Google images: faculty.ksu.edu.sa) 
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Humans are diploid having two copies, one derived from each parent, each of twenty-
three chromosomes, all of which contain many genes.  Thus, we contain two homologous 
(similar) chromosome number ones, two homologous chromosome number twos and so on.  
Through the process of meiosis, each parent contributes only one set of their two sets of 
chromosomes to their offspring.  Fertilization combines the set from each parent thereby creating 
the diploid zygote.  It is important to note, however, that there can be considerable diversity in 
the chromosome set that an offspring inherits from a given parent due to a process known as 
recombination. 
 
DNA – HISTORY  
The quest to discover the genetic material of life began in ~1856 when Gregor Mendel, 
an Austrian monk, began experiments in genetics.  His experiments with pea plants led him to 
formulate the basic laws of heredity (Orel, 1996).  It also led to the growing interest of scientists 
in the study of genetics.  Thomas Hunt Morgan followed this work in 1911 by demonstration that 
genes are located on chromosomes in a linear fashion, furthering the link between heredity and 
our molecular understanding of it (Ruben et…al., 2000).  
In 1928, a British microbiologist named Frederick Griffith carried out experiments 
leading to the demonstration that DNA is the molecule of inheritance.  He worked with the 
disease-causing bacteria Pneumococcus and laboratory mice (ThinkQuest, 2010).  Two strains of 
the bacteria were used: a virulent and a non-virulent strain.  One group of laboratory mice was 
injected with the virulent strain and the other group of laboratory mice was injected with the non-
virulent strain.  The virulent strain had a smooth coat and the non-virulent strain had a rough 
coat.  Those injected with the virulent smooth coated strain died a few days later.  Those injected 
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with the non-virulent rough coated strain continued to be healthy.  He then killed the smooth 
coated virulent strain with heat and injected another group of mice with it.  He observed that this 
group survived.  He then thought that if he were to inject a group of mice with the rough-coated 
non-virulent and the heat-killed strains, the mice would survive.  However when he did this 
experiment, he observed that the mice died.  He thought that the heat-killed virulent bacteria had 
passed on a molecule to the non-virulent bacteria to make it virulent (new trait).  He thought that 
this transforming factor was in the inheritance molecule or gene. He used the term 
transformation to describe the transfer of the inheritance molecule.  
In 1948 Oswald Avery, Colin MacLeod, and Maclyn McCarty came into the picture of 
DNA research.  They continued Griffith’s experiment to see what the transforming factor was by 
destroying the various molecules present in the heat-killed virulent Pneumococcus extract.  They 
destroyed lipids, ribonucleic acids, carbohydrates, and proteins, but still observed that 
transformation occurred.  However, when they destroyed DNA, transformation did not occur.  
Together they had discovered the inheritance molecule, DNA, and confirmed the chemical nature 
of the gene (UDEL, 2004).   
After this discovery, people began to come up with models that would aid in understanding how 
DNA works as an inheritance molecule.  In 1940 a scientist by the name Erwin Chargaff noticed 
a pattern in the four bases: adenine, guanine, cytosine, and thymine (UDEL, 2004).  From 
different cells, he took samples of DNA and realized that the amount of guanine was almost 
equal to cytosine and the amount of adenine was almost equal to the amount of thymine.  This 
finding or discovery later became Chargaff’s Rule.   
The real key to unraveling DNA’s role as the molecule of heredity arguably came from 
the work of four scientists, Rosalind Franklin, Maurice Wilkins, James Watson, and Francis 
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Crick.  Franklin and Wilkins created crystal forms of DNA and used X-Ray diffraction to try and 
deduce the structure of DNA (UDEL 2004; ThinkQuest, 2010).  In 1953 from this work, Watson 
and Crick were able to put together a model of DNA.  When they set their eyes on Franklin and 
Wilkins’ picture, they had enough information to make an accurate model.  Their model has not 
been changed much since then.  Their model described DNA as a double helix with little rungs 
connecting the two strands.  These rungs they realized were the bases of a nucleotide.  A 
problem set them back while they were staring at the model - the pairing of the bases, and also 
the sizes of the bases.  If purines were to pair with purines and pyrimidines to pyrimidines then 
the model will look crooked, but if a purine bonded to a pyrimidine, then the model would be 
uniform.  The pairing they came up with to resolve this problem was the following: Cytosine-
Guanine and Adenine–Thymine. This base-pairing model was consistent with Chargaff’s rule.  
Watson, Crick and Wilkins won a Nobel Prize a few years after the presentation of the DNA 
model. Rosalind Franklin died of cancer prior to the awarding of the Nobel and because they are 
not awarded posthumously she was not awarded a Nobel Prize.  However, it should be noted that 
her work led to this great milestone in genetics and medicine.   
Subsequent to the discovery of the structure of DNA, there have been enormous advances 
in our ability to manipulate DNA  (Nature Review Genetics , 2007).  Rather than present these in 
detail, key advances and discoveries over the past 50 years relevant to the field of genomics are 
highlighted in Tables 1 and 2 below.   
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Table 1: Timeline of discoveries key to the field of Genomics (1950s - 1980s) 
DATE  DISCOVERY RELEVANCE TO GENOMICS 
1952 Electrophoresis Sorting of DNA and RNA 
molecules by size 
1956 Discovery of DNA Polymerase Enzyme that catalyzes the synthesis 
of DNA 
1967 Discovery of DNA Ligase Enzyme that catalyzes the joining 
of two DNA molecules 
1969 Fluorescence in situ hybridization (FISH) nucleic acids can be fluorescently 
tagged and hybridized to 
complementary sequences for 
mapping gene positions and gene 
expression 
1970 Discovery of Restriction Enzymes Enzymes that cut DNA at specific 
sequences 
1970 Discovery of Reverse Transcriptase Enzyme that converts RNA to DNA 
1972  Creation of first recombinant DNA 
molecule 
Ability to generate recombinant 
DNA 
1975 Southern Blot Characterize DNA 
structure/sequence  
1977 DNA sequencing  Nucleic acid sequences could be 
determined 
1977 First genome sequenced  Phage Φ-X174 5368bp 
1980 Discovery of RFLPs (Restriction fragment 
length polymorphisms)  
Sequence differences can be 
detected with restriction enzymes 
1982 Whole genome shotgun (WGS) vs 
directed sequencing  
WGS proposed as means for 
genome sequencing  
1982 Transgenic Drosophila created Modification of higher eukaryotic 
genomes  
1983 RFLPs used to map Huntington Disease Positional cloning of disease genes 
1985  Discovery of Polymerase Chain Reaction 
(PCR) 
Ability to amplify DNA 
1985  DNA fingerprinting Ability to distinguish DNA between 
individuals 
1987 Development of yeast artificial 
chromosomes (YACs)  
Ability to clone large DNA 
fragments (>100kb) 
1987 Development of site directed mutagenesis 
of mouse genome 
Ability to alter mouse genome, 
opens way for gene function studies 
1988 Chromatin immunoprecipitation (ChIP) Provided way to assess protein-
DNA interactions 
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Table 2: Timeline of discoveries relevant to the field of Genomics (1990s - ) 
 
DATE  DISCOVERY RELEVANCE TO GENOMICS 
1990 Creation of Human Genome Project International project to sequence 
human genome 
1990 Development of basic local alignment tool 
(BLAST) 
Provides ability to compare DNA 
sequences, paves way for 
comparative genomics 
1995 Development of Microarray Technology Global analysis of genome 
expression and structure 
1998 Discovery of RNA interference  Ability to inhibit gene function 
1998 Development of pyrosequencing Ability to sequence in a high 
throughput manner 
2001 Publication of 1st human genome 
sequence 
Advent of human genomics 
2001 Launch of Genome Browsers (UCSC 
Genome Browser, Ensembl, NCBI map 
viewer) 
Ability to browse genome sequence 
and annotation online 
2003 Development of DNA assembly programs Ability to reconstruct genome 
sequences from WGS approach 
2004 Development of DNA annotation 
programs 
Ability to annotate DNA sequences  
2005 Creation of first Haplotype Map 
(HapMap) 
Ability to carry out whole genome 
association studies for disease 
susceptibility variants 
2006 Publication of genome-wide maps of 
DNA methylation 
Increased understanding of 
epigenetic phenomena 
2007 Publication of 1st diploid human genome 
sequence 
Paves way for personalized 
genomics 
2008 Publication of variation in eight human 
genomes 
Increased understanding of genetic 
diversity in humans 
2010 Publication of Neanderthal genome Increased understanding of genetic 
ancestry of homo sapiens 
2010 Commercially available genome 
sequencing 
Individuals can have their genomes 
squenced 
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Chapter 2: Genomics – What is it and How is it done? 
Genomics - what is it? 
As described in Chapter One, Mendel’s work in genetics led to the discovery that genes 
are the functional sections of chromosomes responsible for heredity.  Studying and 
understanding the molecular structure and function of genes has been very valuable in providing 
insight to two of the biggest mysteries in biology: what makes a species what it is and what 
causes variation within species.  Through many of the discoveries highlighted in Table 1 and 
Table 2 scientists have been able to gain a better understanding of genes and their roles in 
determining a species characteristics or traits, collectively called a phenotype, and the basis for 
variation of these traits within or between species. By understanding the relationship between 
these genes and the phenotype of an organism or species we can better understand how DNA 
sequences guide heredity.  However, it is important to keep in mind that an organism’s 
phenotype is not simply dictated by its genotype, as the environment is an important contributor 
to an organism’s phenotype.  
Historically, studies on the function of genes and their contributions to phenotype were 
predominantly done on a small scale, gene by gene.  The development of sequencing and 
recombinant DNA technologies dramatically changed the ability to carry out these studies, 
allowing them to be performed on a much larger scale  (Nature Review Genetics , 2007).  This 
led to the development of genomics, a subfield in the field of genetics, whose goal is to 
understand the molecular organization and informational content of the entire DNA sequence, 
genome, of an organism (or species) and its role in directing the phenotype of that organism (or 
species).   
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Genomics – how is it done: Determining genome sequences 
Determination of an organism’s genome sequence is a key first step in genomics and was 
made possible by the discovery of DNA polymerase by Arthur Kornberg in 1956 and the 
development of methods for DNA sequencing, the determination of the sequence of nucleotides 
in a DNA strand, by two different groups in 1977 (U.S. National Library of Medicine, 2010).  
The first method, chain-termination, was developed by Frederick Sanger and involved 
“sequencing by synthesis” – using DNA polymerase to synthesize a strand of DNA 
complementary to the strand of interest (Frederick Sanger et...al., 1977).  By incorporating the 
use of dideoxy-nucleotides, which lack a 3’ hydroxyl and therefore prevent the further addition 
of nucleotides by DNA polymerase, the sequence of nucleotides in the template strand can be 
determined (Frederick Sanger et...al., 1977).  The second method, developed by Allan Maxim 
and Walter Gilbert, was based on modification of the DNA and its subsequent cleavage at 
specific nucleotides.  Since that time “sequencing by synthesis” has been the principal method 
for DNA sequencing (Halima et…al., 2008).   
Sequencing of an individual genome requires four basic steps: (1) preparation of the DNA 
templates, (2) physical sequencing of these templates, (3) imaging/detection of the sequencing 
products, and (4) analysis of the sequence data (Kirkness et…al., 2010).  Among the strategies 
for genome sequencing, whole genome shotgun (WGS) sequencing has becoming the standard.  
With respect to WGS sequencing template preparation (1) involves fragmenting the genomic 
DNA (chromosomes) into many small overlapping pieces.  These small overlapping fragments 
are then subjected to sequencing (2) and the products of the sequencing reaction (3) detected 
(Kirkness et…al., 2010).  Enormous improvements in these latter two steps (2&3) are occurring 
almost daily and diverse technologies exist so they will not be discussed in detail here.  The last 
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step - analysis of the sequence data (4) from all of these fragments has become feasible and 
simplified in large part due to advances in computer science (Kirkness et…al., 2010).  Using 
programs designed to detect overlapping sequences, the sequence of the genome is reconstructed 
in silico, or on the computer.  Together advances in biology, chemistry, engineering, and 
computer science are revolutionizing our ability to rapidly and cheaply sequence genomes on a 
larger scale (Kirkness et…al., 2010).  A future in which an individual’s genome is sequenced as 
a standard part of their medical care is no longer the stuff of science fiction, but has now become 
a reality. 
 
 
 
 
 
 
Genomics and Medicine  Ayisi, Samuel 
 17 
CHAPTER 3:  Medicine - Macroscopic and Microscopic or Pre-Genomics  
Arguably, the determination of the sequence of the human genome has been the most 
profound advance in medicine to date and a world where sequencing is a part of medical care is 
now here.  As such, it is likely to dramatically alter the way we view our health and management 
thereof.  To begin to understand the impact the human genome sequence is having and will 
continue to have on society and health care, this discovery is discussed within a historical context 
of important advances in medicine.  Some of these advances in medicine are highlighted below. 
They lay out a logical progression of understanding the human body that moved from a 
macroscopic level in which medicine was focused on deciphering our physiology and anatomy 
to the current state of medicine, which, arguably, is increasingly focused on a molecular level 
scale to understanding the human body and its health. 
 
Medicine: Transition from spiritual to macroscopic – anatomical & physiological based 
treatment 
The Egyptians and Romans were the first to begin treating diseases physically.  Prior to 
this time, people believed that diseases were caused by spirits or spiritual beings.  As a result 
diseases were treated by so called “spiritual means” by medicine men and magicians.  As time 
went on, the Egyptians and Romans began exploring the anatomy of the human body.  
Anatomical knowledge was attained through the dissecting of corpses and analyzing the various 
structures of the human body.  Treatment of disease was therefore carried out on specific parts of 
the body as a result.  So, for example, if one has pain in the hands, the hand becomes the focus of 
treatment.  This led to the understanding that perhaps diseases were caused by a defect in some 
part of the human body and not just by spirits or spiritual beings.  In other words, they were the 
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first to begin treating diseases based on a general understanding of human anatomy and 
physiology.  Archeological digs have found evidence of people with the title of physicians as 
early as 1500 B.C.  Irj was one of such physicians.  Physicians like Imphotep, a physician to 
King Zoter, lived earlier in Ancient Egypt around 2600 B.C.  Even after his death people 
worshipped him as the god of healing.  As more knowledge about the anatomy of the human 
body was gained, the people gradually drifted away from so-called their “spiritual disease” myth.  
Despite the many myths and spiritual beliefs that had governed people of ancient times, ancient 
Egyptians and Romans and Greeks have provided modern historians with a great deal of 
knowledge and evidence about their attitude towards medicine and the medical knowledge they 
possess. However, documents provide evidence that when diseases could not be treated based on 
anatomical knowledge, patients were still referred to magicians and medicine men.  
 
Medicine: Training Physicians – Development of Medical schools and Medical Education 
Although it is very difficult to identify the origin of medical education, it is believed that 
medical knowledge began with the Greeks use of anatomical knowledge and rational inquiry to 
treat diseases (Garrison, 1921).  This inquiry introduced the process of observation and reasoning 
regarding disease.  This rational inquiry is believed to have led to teaching and thus the 
formation of medical schools such as that at Cos, which Hippocrates, the most famous of all 
ancient Greek doctors, founded in the 5th Century B.C. (Garrison, 1921). Though there were 
other physicians during his time, Hippocrates was the man leading the development of medicine 
in Greece and many see this man as the father of modern medicine even though he was born in 
Cos in 406 B.C. (Garrison, 1921).  
Hippocrates believed in keeping the treatment of diseases away from spiritual beliefs and 
Genomics and Medicine  Ayisi, Samuel 
 19 
in treating the body as a whole and not as separate parts as ancient knowledge of anatomy 
suggested.  In other words, Hippocrates set the tone for understanding the physiology of the 
human body as a crucial aspect of medicine.  He was also the author of some of the collection of 
sixty medical books that summed up ancient Greek medical knowledge (Garrison, 1921).  This 
collection of books, the Hippocratic collection, was named after him even though evidence show 
that he didn’t write a majority of these books, which covered a span of 150 years.  The collection 
deals with anatomy, clinical subjects, diseases of women and children, prognosis, treatment, 
surgery and medical ethics.  He was famous to the point that famous people like Aristotle and 
Plato wrote about him and his work made such a great impression on medicine that his name is 
still associated with medicine today.  When medical students receive their medical degree they 
take the Hippocratic Oath, written by Hippocrates, before they are allowed to administer 
medicine (Garrison, 1921). 
It is believed that Cos’ medical institution was first to be ever built.  Later, the Christian 
religion greatly supported the cause of not only treating disease but the establishment of 
institutions to produce physicians.  During the middle ages, apprenticeship training in monastic 
infirmaries and hospitals dominated medical education.  Medical schools like the current ones 
did not evolve until between the 9th and 11th centuries which saw the establishment of one in 
Salerno in Southern Italy.  Even there, the teaching style was still by the apprentice system. The 
apprenticeship system was still in use because a clear-cut curriculum for medicine hadn’t been 
established.  After a while, an attempt was made at systemization of the medical knowledge of 
the time.  Through this process, a series of health precepts was drawn up and approved for 
medical practice by the then Holy Roman Emperor Frederick II.  During the same time, the 
Muslim world also saw similar developments.  Medical institutions were established in cities like 
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Cairo, Baghdad and Cordoba (Garrison, 1921). 
The development and establishment of Universities in Europe also had an impact on 
medicine.  Medical studies led more often to familiarity with theories about disease than with 
actual sick people.  However, the establishment of the Royal College of Physicians of London in 
1518, through the energy of people like Thomas Linacre, produced a system that examined 
medical practitioners before they were authorized to practice medicine.  The discovery of blood 
circulation by William Harvey also allowed for a scientific approach to the study of medicine.  It 
also didn’t support the tradition of studying the body through theories and doctrines (Garrison, 
1921). 
During the 17th and 18th centuries, this new practical approach to studying medicine, 
which preached the value of hospital experience, was reasserted (Rothstein, 1987).  It also saw 
the training of student’s sight, hearing and touch as the best way to apply increasing knowledge 
of natural science to the actual care of patients.  There was also an encouragement of the 
systematic study of anatomy, chemistry, and botany, sciences that were considered to be the 
basis of medicine at that time (Rothstein, 1987).  During these colonial times in England, three 
distinct groups practiced medicine: physicians -university trained, surgeons - apprenticed and 
hospital trained, and apothecaries - also apprenticed.  In America, however, the distinction 
between physician and surgeon soon disappeared.   The New Jersey Medical Society, chartered 
in 1766, represented the first group of medical professionals in America and paved the way for 
the development of training programs – medical schools (Rothstein, 1987).  In the mid 1800s the 
American Medical Association (AMA) was formed and set educational standards for the practice 
of medicine  (Rothstein, 1987).   
These included: 
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 1) liberal education in the arts and sciences, 
 2) certificate of training completion from preceptor over apprenticeship prior to  
entrance to Medical college, 
3) an MD degree of 3yrs of study (2 six month lecture sessions, three months of  
dissection, at least 1 six month session of hospital training), 
4) 16 week course in anatomy, medicine, surgery, midwifery, and chemistry, and 
5) minimum 3yrs of study at least 2 under practitioner. 
 
In America, the John Hopkins University School of Medicine in Baltimore became 
known as the first medical school.  From there, the adequacy of medical schools was further 
improved by the Flexner report written by Abraham Flexner and published by the Carnegie 
Foundation for the Advancement of Teaching (Rothstein, 1987).  In this report written in 1910, 
he outlined that medical education is actually a form of education rather than some 
apprenticeship.  Also, this report clearly laid out what medical schools needed to be successful: 
laboratories, teaching rooms or lecture halls, libraries, large hospitals where the medicine can be 
practiced, an academic staff, etc.  It was after this report that medical schools really advanced in 
the United States.  
 
Medicine: Important Technical Advances in Treatment 
 Microscopes: The microscope is arguably one of the greatest inventions that man 
has ever made.  In 1590, the compound microscope was invented by two spectacle makers, Hans 
Jannsen and his son (Hogg, 1854).  In the 16th and 17th centuries, Italy and Holland were 
principal countries for the construction and use of microscopes.  Galileo left a mark on this 
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invention by making several telescopes and microscopes that he called “ochialino” (Hogg, 1854).  
However, the word microscope was coined by an Italian, named James Faber, in 1625.  Petrus 
Borellus in 1653 published a paper on the use of microscopes in medicine. In his paper, he 
described 100 medical observations and applications of microscopes including how to remove 
invisible in-growing eyelashes (Hogg, 1854).  These observations opened doors for research into 
the cause of diseases using microscopes.  Athanasius Kircher observed microscopic worms in 
plague victims, which he suspected killed millions of people in Europe during the 17th century. 
Most likely, he was looking at pus or cells in the blood because microscopes then could not see 
the Bacillus pestis that was causing plague (Hogg, 1854).  
 Brilliant observations made by Anton von Leeuwenhoek with his microscope excelled 
those of all microscopists at that time.  Through his observations, he gave descriptions and 
illustrations of bacteria from the human mouth, spermatozoa, skeletal muscles, protozoa, and 
epithelial cells from warts.  He is also known for his brilliant observation of red blood cells. 
Malpighi, another brilliant microscopist, histologist, and embryologist, was the first person to see 
anastomosis between arterial and venous capillaries. Every medical student knows his 
description of the Malpighian bodies of the kidney, the Malpighian corpuscles of the spleen and 
the Malpighian layer of the epidermis—among his great observations. Despite all this great 
observations and findings, clinical microscopy had a very slow beginning. It took more than two 
centuries before the value of microscopes began to be appreciated by clinical and laboratory 
scientists.  As time went along electron microscopes were developed to even look at the smallest 
of all microbes.  DNA was also first observed using this type of microscope (Rayment, 2010).   
 Anesthesia: Anesthesia is simply defined as the loss of feeling or sensation. 
Currently, this is a process used before all surgeries. This process was first used by an American 
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Physician, Crawford W. Long , in an operation in 1842 (Canton, 2007).  However it was not 
recorded so official credit was given to William Morton in 1846 for demonstrating an operation 
involving anesthesia (Canton, 2007).  It had a major impact because it allowed surgeons to do 
surgery without worrying about the pain that patients will go through during the process of 
surgery.  
Prior to anesthesia, ancient methods were used to control pain during the process of 
surgery, including the use of drugs such as alcohol, hashish, and opium derivatives (Garrison, 
1921).  Also used were rudimentary physical methods of producing insensitivity to pain. These 
include packing limbs on ice, and an extreme method of inflicting a blow to the head.  These 
methods performed the job of reducing pain but weren’t safe.  A safer method, anesthesia, began 
after the discovery of nitrous oxide by English Chemist Joseph Priestly in 1772.  Ether, a similar 
gas, also became popular in the United States at that time.  Attention returned to nitrous oxides 
when Horace Wells, a Connecticut dentist, learned about the effects of nitrous oxides by testing 
it on himself and his patients.  He was happy with the results, so he shared this information about 
nitrous oxide with his friend William T. Morton, a student at Harvard medical school, who 
proceeded on a quest to find an even more potent agent. He began experimenting with sulfuric 
ether.  Pleased with the outcome of the experimentation, he contacted a Harvard University 
colleague Dr. John C. Warren who would arrange for a public demonstration of surgery without 
pain using sulphuric ether.  News of this spread worldwide and a new era of surgery was born. 
Oliver Wendell Holmes would later coin the term anesthesia to describe the condition brought on 
by ether (Canton, 2007). 
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 Antibiotics: An antibiotic is a substance that kills bacteria or inhibits their growth.  
The term “antibiotic” was coined by Selman Waksman, in 1942, to describe any substance that is 
antagonistic to the growth of microorganisms.  It came from the word “antibiosis”, term coined 
by Louis Pasteur’s pupil Paul Vuillemin in 1889, which means a process by which life could be 
used to destroy life. The original definition excluded naturally occurring substances that were not 
produced by microorganisms, but performed the same function of antagonism against bacteria.  
It also excluded synthetic antibacterial compounds such as sulfonamides. However as time went 
by, these exclusions became a part of the definition (ThinkQuest, 2010). 
  During ancient times, Egyptians, Chinese, and Indians of Central America all 
used molds to treat infected wounds without really understanding the antibacterial properties of 
it.  However, the true search for antibiotics began in the 1800s with the growing acceptance of 
the germ theory of disease which linked microbes like bacteria to the causation of diseases.  The 
search started when scientists worldwide began to figure out ways to take care of microbes that 
cause diseases. The quest began 1871 with surgeon Joseph Lister researching the phenomenon 
that mold-contaminated urine would interfere with the growth of bacteria.  In 1890, the first 
antibiotic made up of microbes to be used in hospitals was made by German doctors, Rudolf 
Emmerich and Oscar Low. They named it pyocyanase. However, it didn’t work as often as was 
expected (ThinkQuest, 2010). 
In 1928 Sir Alexander Fleming demonstrated antibacterial properties by observing that the mold 
Penicillium notatum could destroy colonies of Staphylococcus aureus. This led to the biggest 
impact on medicine by antibiotics with the isolation and manufacturing of Penicillin by Howard 
Florey and Ernst Chain in 1942.  Penicillin could now be sold as a drug.  Fleming, Florey and 
Ernst were awarded the Nobel Prize in medicine in 1945 for their work on Penicillin.  Penicillin 
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was the first working antibiotic. Currently it is still in use in hospitals to fight bacteria, though 
some bacteria have grown to be resistant to it. In 1935, Pronotosil, the first sulfa drug, was 
discovered by German Chemist Gerhard Domagk.  In 1943, the antibiotic streptomycin, a drug 
made out of soil bacteria, was made by the American microbiologist Selman Waksman.  
Streptomycin would introduce a new class of drugs called aminoglycosides.  Streptomycin could 
treat diseases but its side effects are often too severe.  In 1955 Lloyd Conover patented 
Tetracycline, which would go on to become the most prescribed broad spectrum antibiotic in the 
United States.  In 1957 Nystatin was patented and used to treat many disfiguring and disabling 
fungal infections.  SmithKline would hit the market with Amoxicillin, a semisynthetic antibiotic, 
in the 1981 (ThinkQuest, 2010). 
 Antibiotics changed the way we looked at and approached the treatment and cure 
of many diseases.  With the invention of microscopes and discovery of microbes, the concept of 
“germ theory”, diseases caused by microbes, was developed.  Such diseases could be treated by 
attacking the microbes that caused them through the use of antibiotics.  That this concept is still 
important and impacting medicine is typified by the awarding of the Nobel prize in 2005 to 
Barry J. Marshall and J. Robin Warren for their discovery that gastritis and peptic ulcer disease 
was caused by the bacterium Helicobacter pylori (ThinkQuest, 2010). 
  
 In vitro fertilization: Infertility is the inability of a couple to become pregnant.  
Currently 10% - 6 million, of the general American population are affected by infertility 
(Bavister, 2002).  To help treat this condition, Dr. Robert G. Edwards developed the process of 
in vitro fertilization.  In in vitro fertilization egg cells are fertilized by sperm cells in a test tube - 
outside the body.  Through this procedure, zygotes (fertilized egg) or embryos can then be 
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transferred into the uterus and result in pregnancy.  It was successfully used for the first time in 
1978 with the birth of the first test tube baby, Louise Brown (Bavister, 2002).  Since then more 
than 250 babies have been born as a result of this wonderful technique.  Dr. Brown was awarded 
the Nobel Prize in Physiology or Medicine for his work in developing this treatment in 2010.  
 
Medicine: Transition to the Molecular Level 
 As medicine was transitioning to a cellular scale with the discovery of microbes and the 
development of techniques such as in vitro fertilization, our understanding of DNA and its role in 
human biology was becoming increasingly clear.  As such, it was inevitable that medicine would 
begin to seek information on diseases at the molecular level.  This was first done for sickle cell 
anemia, which in 1910 was shown to have defects at the cellular level – “peculiar elongated and 
sickle-shaped” cells by Ernest Irons and Dr. James Herrock.  The disease showed evidence of 
inheritance, supporting a genetic basis. This was confirmed in 1949 by Linus Pauling with the 
demonstration that sickle cell anemia was due to an abnormal form of the protein hemoglobin  
(Pauling, 1959). 
This discovery ushered in the future of medicine at the molecular level and led to the 
field of genetic counseling which was created to help patients better understand the impact of 
genetic information on their health.  In 1971 the first genetic counselors graduated from Sarah 
Lawrence College (Coutts, 1994).  Genetic testing for specific diseases has now become 
commonplace and in 1990 Ashanti DeSilva, a patient with severe combined immune deficiency 
(SCID), was the first person approved for gene therapy in the United States.  In this technique, 
the disease is treated at the molecular level by providing a functional version of the affected gene 
to the genome of the diseased individual.  In Ashanti’s case, the nonfunctional form of adenoside 
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deaminase (ADA) in her genome was compensated for by inserting a functional form of the 
ADA gene into her cells.  In Chapter 4, the impact of this transition to a molecular understanding 
of disease and of genomics on medicine is explored in greater detail. 
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Chapter 4: Medicine - The Impact of Genomics 
 
Many advances in genetics have been made since the discovery of DNA about 70 years ago.  
All these advances have gotten the world closer to the ultimate goal of deciphering genomic 
information for a positive impact on society.  However in 2001, the world saw a major 
breakthrough with the sequencing of the first human genome.  If this had been predicted by 
anyone around the time of DNA’s discovery, the world would have said it was impossible. The 
Human Genome Project began in 1990 and amounted to a total cost of ~$2.7 billion.  Though 
very expensive by today’s standards where genomes can be sequenced for $1000-$20,000, it is 
impossible to put a cost on the impact of the human genome project.  It has moved the world into 
a new era and in a short time dramatically impacted our approach to medicine.  
Prior to genomics, discoveries in biology provided incremental advances about genes—their 
regulation, expression, and function.  With the advent of the human genome sequence, the world 
of science has been able to address gene function on a much larger scale.  With respect to 
medicine, scientists have focused on a couple of questions: what does the sequence mean and 
how can genomic data be used to treat disease?  These are complex questions and many of the 
answers lie in the future.  However, among the simple answers we have learned is that as 
increasing numbers of individual genomes are sequenced, more insight is gained.  This means 
that more people would need to agree to get their genomes sequenced so that research can be 
conducted over a large scale.  However, cost and ethical and legal issues remain paramount 
concerns.  
Since the Human Genome Project, which amounted to almost $3 billion, the cost of 
sequencing has decreased dramatically.  This is due to the great advances in the sequencing 
technology, which has made the entire process quicker and more efficient.  Currently with next 
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generation sequencing technology, a human genome can be sequenced for less than $10,000 and 
there is a bold prediction that this figure could decrease to $1000 per human genome in the 
future (Samani et al, 2010).  Any economist would agree with the following statement: As the 
cost of a product decreases, there is always an increase in the amount of consumers for that 
product as opposed to more costly products that serve the same purpose.  This will be no 
different for genome sequencing.  For more people to be willing to sequence their genomes, the 
cost of sequencing needs to be reduced.   Many private companies foresee opportunity in this 
technology and are aggressively working to reduce the cost, leading to the predictions of $100 
genomes in the near future are not met with great skepticism any more.  
More important than the cost of a genome sequence, is that society attempts to understand the 
benefits of this information and the ethical and legal issues that arise from having access to 
people’s genome sequence.  Despite the many issues, with private companies and members of 
the scientific community behind these efforts genomics has already impacted medicine in two 
very specific ways.  First, the sequence of an individual’s genome will provide direct information 
of relevance to his or her own health.  This can lead to management of one’s health in a highly 
individualized way, setting the stage for an era of “personalized medicine”.  Second, the ability 
to analyze genome sequences from large populations of individuals of similar and differing 
ethnic backgrounds, medical conditions etc. has begun to yield important information about the 
links between DNA sequence, human biology, and disease. 
 
Genomics & Personalized Medicine 
Increasing advances in genomic research have led to personalized medicine.  This is an 
approach in which care is administered to a patient based on personal information about the 
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patient.  Previously, personalized medicine had been administered with minimal to no 
information on a patient’s genetic makeup.  Given that our phenotype (and health) is dictated in 
large part by our genetic makeup, excluding this information from the diagnostic process seems 
destined to result in an incomplete and potentially inaccurate picture. With an individual’s 
genome sequence in hand, doctors can now add this information to more standard obtain a more 
complete picture of the patient’s health.  This opens the door to developing treatments or health 
management plans based in part on the results of the patient’s own genetic makeup.  
Key to the wide spread use of personalized medicine will be commercially available, low-
cost genome sequencing.  With the belief in a large market demand in the near future, a number 
of companies have begun to offer genome-sequencing services.  The services they offer do not 
require a physician or other health care professional and instead provide results directly to the 
consumer.  Such services are known as Direct-to-Consumer (DTC) services.  Currently, the 
majority of these services are offered online (Knoppers, 2010).   
Recently, however, companies have embarked on efforts to bring these services onto the 
local the drugstore shelves.  A notable example of this occurred in the summer of 2010 and 
involves Pathway Genomics.  Pathway went into a contract with Walgreens, a nationally known 
Pharmacy to provide a genetic testing kit (Rugnetta, 2010).  Under their agreement, Walgreens 
would sell Pathway’s genetic test kit at 6000 Walgreens pharmacies nationwide (Rugnetta, 
2010).  However, the execution of the contract didn’t happen because the United States Food and 
Drug Administration (FDA) stepped in.  According to the FDA who sent out a letter to Pathway 
Genomics just when the product was about to hit the market, Pathway Genomics was selling 
what appeared to be a medical device under section 201(h) of the Federal Food Drug and 
Cosmetics act.  This act defines a medical device as an instrument that is intended for use in the 
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diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of 
disease (Rugnetta, 2010).  As part of the kit/service Pathway Genomics would sequence regions 
of the individual’s genome and would scan their genes for a propensity for various diseases, such 
as breast cancer, diabetes, Alzheimer’s, etc. (Rugnetta, 2010).   
As of the end of 2010, the FDA is still investigating the legal ramifications of what Pathway 
Genomics offers and their product is pending approval.  Curiously, while this off the shelf 
product is on hold, the online services are still being offered and results are mailed directly to 
consumers (or their doctors).  Additional genome services provided online by companies include 
health risk tests, single nucleotide polymorphism (SNP) tests for the whole genome, and ancestry 
tests, among others.  Table 3 below shows a list of some of these companies, what they offer, the 
cost of services, and how they distribute the results of their tests.  
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Table 3:  Companies providing DTC Genome Services 
 
Company  Services Cost 
 
Mechanism of  
Data 
Distribution 
23and Me -­‐ Ancestry test 
-­‐ Health risk tests for 119+ 
conditions 
-­‐ Complete package of 
both 
 
$499 for ancestry and health gene scan 
package 
N.B: 2010 Christmas sale for $99  
 
Separate tests also offered: 
Ancestry tests alone = $399  
Health edition (testing genetic risks for 
119+ conditions = $425 
Data sent to 
consumer and 
consumer logs onto 
website where there 
are tools that help 
them analyze the data 
Pathway 
Genomics 
-­‐ Health Test Scan for 90+ 
conditions 
-­‐ Ancestry Test (1000 
maternal + 200 Paternal 
haplogroups) 
Health Test Scan (tests for genetic risks 
for 90+ conditions = $299 
Ancestry Test (gauged 1000 maternal + 
200 paternal haplogroups) = $199 
 
20% discount on all prices for 
OptumHealth Allies’ members  
Testing requires 
physician approval, 
data provided online 
to both consumer and 
physician 
Navigenics -­‐ SNP-genotyping test for 
whole gene  
 
-­‐ Genetic predisposition 
test to 10 common health 
conditions  
SNP-genotyping =$999 
Genetic predisposition data = $499  
NA 
DecodeMe -­‐ Full service providing 
genetic risk for 42 
conditions 
-­‐ Cancer Scan including 
genetic risk or 7 cancers 
-­‐ Cardio Scan testing 
predisposition to 
cardiovascular events like 
heart attacks and atrial 
fibrillation 
Full service scan =$985 
Cancer scan= $225 
Cardio Scan = $195  
  
NA 
New Hope 
Medical  
Genetic testing for 
between 12-25 SNPs 
linked to certain 
conditions 
between $475 and $900 NA 
Gene Essence Genetic testing using 
affymetrix 6.0 SNP array 
giving 1 million genetic 
variants (SNPs) and 
calculation of  genetic 
susceptibility  for 
common diseases and 
complex traits 
= $1,195 NA 
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Table 3 (cont.):  Companies providing DTC Genome Services 
          
Company  Services Cost 
 
Mechanism of  
Data 
Distribution 
Knome Full genome scans $350,000 NA 
Illumina  Whole Genome 
sequencing  
$48,000 NA 
Vugene 1.Basic Alzheimer’s test 
2.Alzheimers’ for 
Women 
3. OSA 
4. Stroke Test 
5. Weight Loss Success 
Test 
1. $99.95 
2. $109.95 (sale price 20% off ) 
3. 69.95 
4. $49.95 
5. $89.95 
 
NA 
Oxford 
Nanopore 
Powerful and affordable 
whole genome 
sequencing 
 NA 
Life 
Technologies 
Combo of companies  
have come together to 
improve sequencing  
 NA 
Pacific 
Biosciences 
New technology for 
whole genome 
Sequencing 
 NA 
Helicos 
Biosciences 
True single-molecule 
sequencing TM Platform 
 NA 
GnuBio Whole genome 
sequencing  
$45,000 
 
NA 
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 One may ask, so what does knowing information about ones genome does for them?  What 
is the significance of such information?  This question is better answered by answering the 
question: what are the applications of personalized genomic data?  Though there are increasing 
numbers of DTC companies seeking to offer personalized genome sequencing services, our 
understanding of what this information means is still in its infancy.  Even though predisposition 
services are offered by DTC companies the multifactorial nature of many diseases suggests that 
caution is necessary when interpreting the data.  
Since the development of genome sequencing, there have been a handful of applications of 
personalized medicine.  One of the major areas of application has been in cancer research.  
Cancer is triggered by a cascade of mutations resulting in an activation of oncogenes or 
inactivation of tumor suppressor genes.  In August of 2010, the first example of genome-scale 
RNA and DNA sequencing to aid in clinical decision and therapeutic choice was published in the 
journal Genome Biology (Agency, 2010).  The disease under research was a rare tumor on the 
tongue which had progressed to metastatic disease.  Because of the rarity of this disease, no 
established treatment option for the disease existed.  For the first time, scientists turned to the 
analysis of whole genome sequences – this allowed for the comprehensive discovery of genetic 
changes that had accumulated within the tumor.  From the results of the analysis, a personalized 
drug regime was initiated to stabilize this aggressive cancer for several months (Agency, 2010).   
This is a major advance and represents an important milestone in the use of genomics in 
medicine - treatment was tailored to an individual based on their genetic makeup.  With the 
number of such instances increasing, it is safe to say the promise of genomics to personalize 
medicine is no longer a promise, but is now upon us.  Although arguable, it is likely that 
therapeutic treatments will ever more rely on an individual’s sequence as the primary source of  
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information. 
 
Genomics & Global Medicine 
Genomic research is also greatly impacting how we treat disease on a global scale. As a 
matter of fact the field of global medicine was the first to be impacted.  Right after the 
sequencing of the entire human genome in 2003, it became clear that to make sense of genomic 
data comparisons among individuals had to be made.  This led to projects like the Personal 
Genome Project, which aims to sequence the genomes of a group of individuals (on a volunteer 
basis) so such comparisons can be made. 
Global healthcare deals with healthcare that is administered worldwide with considerations to 
the various regions around the world.  There are ongoing efforts to improve global healthcare 
based on the different regions in the world.  A case study conducted in a few regions around the 
globe revealed that DNA sequences slightly differ with respect to regions around the globe.  As a 
result, medicine and treatments could be developed in such a way that target would be regionally 
or ethnically based.   
Case studies were conducted in four countries in different regions around the world: Mexico, 
South Africa, India and Thailand, to assess the effect of genome information on medicine from a 
global perspective.  In Mexico, the National Institute of Genomic Medicine (INMEGEN) was 
established in 2004 to carry out disease-related genomic studies (Singer et al, 2008).  This 
organization aims to develop public health genomics in Mexico.  The organization has begun 
studying genomic variations in sub-populations as a starting point.  Mexico foresees the health 
and economic benefits that gaining genomic knowledge could bring.  As a result, significant 
monetary investments have been made toward ensuring the success of INMEGEN.   
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In South Africa, a number of initiatives have already been made to study genetic variation 
within the local indigenous populations.  South Africa is also beginning to apply genomics to 
address local health needs, including Human Immunodeficiency Virus (HIV) and Tuberculosis 
(TB) infections.  South Africa even has an organization-- Africa Genome Education Institute, 
responsible for involving the public in genomic issues (Singer et al., 2008).   
India, with the second largest population in the world, is also looking for high-tech science 
and technology that would improve its economic and health situations.  Thus, India is also now 
working to develop genomics in the country through the Indian Genome Variation (IGV) 
Consortium, a government-funded collaborative network among seven local institutions (Singer 
et al., 2008).  One of the goals of the Consortium is the identification of links between specific 
genome variants and disease, which would then be used to improve treatment options on a 
national scale. 
Finally, Thailand has also been involved in efforts to use genomics to improve healthcare. 
Specifically, Thailand has launched two genotyping initiatives: the Thai SNP Discovery Project 
and the Thai Center for Excellence in Life Sciences Pharmacogenomics Project. Together these 
projects will help Thailand understand the genomic diversity of its population and how to predict 
drug response with this information. A big challenge is foreseen, however - Thailand will have to 
figure out a way to incorporate this knowledge into its young universal health-care system 
(Singer et al., 2008). 
These case studies reveal the incredible impact that genomics is having on developing 
countries.  It also reveals that genomics is having an impact globally on both poor and rich 
countries despite the economic challenges currently involved with genomic medicine.  Countries 
have shown interest because increasingly genomics is positively impacting health and economic 
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situations.   
One particular area in medicine that has taken a global initiative to use genomic data to treat 
diseases is in cancer research.  Cancer is defined as the uncontrolled growth of cells caused by 
mutations in the human genome.  Complications in cancer research stems from the fact that 
cancer is not caused by a single mutation, but rather a series of mutations.  To make the situation 
even worse these mutations are not only point mutations, but are a combination of deletion, 
insertion, inversion, and repeat mutations. This makes identifying the major gene contributors to 
specific types of cancer very challenging.  
To overcome this, a global effort to fight cancer with genomic information was first initiated 
in 2006 with studies of 35 colorectal cancers. Initially, this didn’t reveal the gene primarily 
mutated in this type of cancer.  Surprisingly, IDH1I, isocitrate dehydogenase - a lowly 
housekeeping enzyme involved in metabolism, was later proven to be among the many mutated 
genes in colorectal and other cancers.  It was not until 300 more of such cancers were analyzed 
to confirm that IDH1I was in fact involved (Ledford, 2010).  However there are many more 
genes yet to be discovered as components in causing cancer.  In the past two years, labs around 
the world have teamed up to sequence thousands of genomes from tumor cells along with 
healthy cells from the same individuals (Ledford, 2010).  The hope is that from the wealth of 
sequence information key mutations will appear again and again to help identify key pathways 
involved in cancer formation.  
Along these lines, the International Cancer Genome Consortium (ICGC), formed in 2008, is 
coordinating efforts to sequence 500 tumors from each of fifty cancers—a project estimated to 
cost about $1 billion. Eleven countries have already signed on to cover twenty of these cancers. 
Table 4 shows the countries involved and the cancers they are working with.  It is estimated that 
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it would cost $20 million to sequence each cancer type, but with help and funding from the 
countries and organizations like the European Union, the project is already under way (Ledford, 
2010). 
 
Table 4: Genomics and Global Cancer Research 
Country Number of Cancers 
Sequenced  
Types of Cancers Being Sequenced 
United States 6+ • Ovarian Cancer 
• Brain Cancer 
• Lung Cancer (squamous-cell carcinoma) 
• lung cancer (adenocarcinoma) 
• Acute Myeloid leukaemia 
•  colon cancer (adenocarcinoma)  
Britain 3 • Breast Cancer (ER-, PR-, HER-) 
• Breast Cancer (Lobular) 
• Breast Cancer (ER+, HER-) 
France 3 • Breast Cancer (HER2 Overexpressing) 
• Liver Cancer (Alcohol-Associated) 
• Renal-cell Carcinoma 
Australia  2 • Pancreatic Cancer (ductal adenocarcinoma) 
Canada  1 • Pancreatic Cancer (ductal adenocarcinoma) 
Germany  1 • Pediatric brain tumors 
Spain 1 • Chronic Lymphocytic Leukemia 
India 1 • Oral Cancer (gingivobuccal) 
Italy 1 • Rare Pancreatic Cancers (enteropancreatic 
endocrine, pancreatic exocrine) 
Japan 1 • Liver Cancer (Virus- Associated) 
China 1 • Gastric Cancer 
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One issue that the ICGC project doesn’t address is the issue of functional link to cancer 
development.  The appearance of specific mutations in certain cancers is strictly correlative.  
Therefore, to address the functional relationship issue, the US National Cancer Institute 
established two 2-year cancer projects in September of 2010 to look into high-tech methods for 
testing the cellular function of mutations identified from the project.  Sites for this project are 
Dana Farber Cancer Center in Boston and Cold Spring Harbor Laboratory in NY.  The ultimate 
goal of these two projects is to find a systematic way by which researchers can make sense of the 
mutations that are being identified in tumor cell genomes. Specifically, the Boston site is 
responsible for increasing and reducing the expression of correlated genes in cell cultures.  In 
contrast, the Cold Spring Harbor site studies cancer-associated mutations using tumors 
transplanted into mouse.  Together, these laboratories look to pave the way for us to understand 
and navigate through genomic data in cancer (Ledford, 2010).  
 
Genomics & Global Medicine 
Though genomics promises a bright future for healthcare, a few issues need to be resolved 
for the success achievement of this ultimate goal. Genomics is faced with both ethical and legal 
issues at the moment.  The public is concerned about privacy.  These concerns, beginning in the 
1990s, were largely triggered by the Human Genome Project (HGP) and the establishment of 
population bio-banks in the following decade (Knoppers, 2010).  Lawmakers were worried that 
genetic information could be used for discrimination purposes.  This led to legislation both in the 
USA and Europe to protect the privacy of genetic information and prohibit genetic 
discrimination (Knoppers, 2010).   Despite these protection laws, the public is still worried about 
how genetic information is distributed.  Concerns were stirred up by popular online genetic 
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testing services that offer predictions to consumers of their health risks.  Of paramount 
importance and concern to the public is ensuring the accuracy of information reported to 
consumers.  In addition, the public is concerned about how this information could be distributed 
or used for research.  Who gains access, the consumer, their doctors, and/or insurance 
companies?  This is a big problem because if someone has a predisposition to some serious 
medical problem like cancer, an insurance company could pass on giving this person medical 
insurance.  To resolve such issues, governments would have to set up legislation to prevent this 
from happening.  This occurred in the U.S. in May of 2008 when President George Bush signed 
the Genetic Information Nondiscrimination Act into Law.  This law prevents the improper use of 
genetic information to deny insurance and affect employment. This is an important first step in 
insuring consumers protection from the inappropriate use of their genetic information.  However, 
a more complete understanding of all the legal and ethical issues surrounding genomics will 
require significant work in the future. 
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Chapter-5: Project Conclusions and Projections   
Genomics has and continues to have a big impact on medicine. Looking at its impact personally 
and globally, it is fair to say that the future of medicine is dependent on our ability to identify, 
interpret, and possibly manipulate genomic information.  When this in mind, doctors ability to 
make accurate diagnoses and carry out treatments will be greatly impacted.  Patients on the other 
hand may feel more comfortable because treatments are being personalized based on our 
understanding of the human genome.  As mentioned earlier, the goal of using genomics to 
improve medicine is far from being attained.  Through genetic testing companies can provide 
predictive healthcare information, but to make solid, accurate, and factual conclusions that would 
impact medicine, the mystery behind the human genome needs to be unraveled.  With all the 
focus on genomics, the mystery promises to be unraveled in our lifetimes.    
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